Skip to main content

Table 1 Protein expression differences among experimental groups at different time points (30 min, 1 h, 4 h and 48 h)

From: Changes in serum proteins after endotoxin administration in healthy and choline-treated calves

LPS_Choline P02081; Hemoglobin fetal subunit beta/1.52
Q9QAQ7; Non structural protein of 4 9 kDa/3.42
P02676; Fibrinogen beta chain/3.83
A2I7N1; Serpin A3 5/1.44
Q3ZC07*; Actin alpha cardiac muscle 1/15.21
Q32L76; Serum amyloid A 4 protein/1.70
A2I7N3; Serpin A3 7/1.44
Q3ZC07*; Actin alpha cardiac muscle 1/187.33
P0CH28*; Polyubiquitin C/1.59
P12799; Fibrinogen gamma B chain/8.44
Q2M2T2; U-p-C19orf71-h/2.17
P02676; Fibrinogen beta chain/64.53
A2I7N1; Serpin A3 5/1.44
Q9TTK6; Membrane primary amine oxidase/Infinity
P01966; Hemoglobin subunit alpha/1.50
P19034; Apolipoprotein C II/2.82
Q9MYP6; beta hydroxysteroid dehydrogenase 14/26.44
Q1JQ97; Bardet Biedl syndrome 4 protein homolog/2.30
Q9TTK6; Membrane primary amine oxidase/11.79
P81644; Apolipoprotein A II/1.45
P19035; Apolipoprotein C III/2.34
Q32L76; Serum amyloid A 4 protein/2.20
Q5E9E3; Complement C1q subcomponent subunit A/3.01
P34955; Alpha 1 antiproteinase/1.60
P28800; Alpha 2 antiplasmin/1.43
P80012; von Willebrand factor Fragment/2.98
Q9TTE1; Serpin A3 1/2.09
Q80E01; Glutaredoxin 1/2.21
Q3SZJ0; Argininosuccinate lyase/1.81
Q17QL1; Glucosamine 6 phosphate isomerase 2/2.96
Q3T0Z5; Leukocyte receptor cluster m-1-h/2.22
Q9TTE1; Serpin A3 1/1.74
Q9TTK6; Membrane primary amine oxidase/64.58
A2I7N0; Serpin A3 4/1.47
P41361; Antithrombin III/2.67
P00735; Prothrombin/2.287
P12799; Fibrinogen gamma B chain/5.92
 
LPS P17697; Clusterin/1.43
Q0V898; Negative elongation factor E/1.68
Q9TTK6; Membrane primary amine oxidase/7.17
A6QPQ2; Serpin A3 8/1.67
O46406; Primary amine oxidase lung isozyme/3.74
P01044; Kininogen 1/2.13
A7E3W2; Galectin 3 binding protein/13.09
P41356; Fusion glycoprotein F0/1.82
O62830-2; Isoform Beta 2 of Protein phosphatase 1B/6.78
Q3T132; Ragulator complex protein LAMTOR2/189.56
Q3SZJ0; Argininosuccinate lyase/9.22
Q9QAQ7; Bovine coronavirus strain OK 0514 GN 4a/4.93
Q0V898; Negative elongation factor E/10.86
Q28901;6-p-2-k-f-2-6-b-f/Infinity
A2I7N2; Serpin A3 6/1.64
P81644; Apolipoprotein A II/1.62
P19035; Apolipoprotein C III/2.80
Q5E9E3; Complement C1q subcomponent subunit A/2.66
Q28901; 6-p-2-k-f-2-6-b-f/infinity
P01966; Hemoglobin subunit alpha/1.81
P02081; Hemoglobin fetal subunit beta/1.55
P80109; P-g-s-p-d/1.50
Q5E9F5; Transgelin 2/2.90
P22226; Cathelicidin 1/13.17
Q7SIH1; Alpha 2 macroglobulin/1.41
A2I7M9; Serpin A3 2/9.68
P00924; ENO1 YEAST Enolase 1/1.46
Q3MHN5; Vitamin D binding protein/1.67
Q3ZC07*; Actin alpha cardiac muscle 1/25.52
P80109; Phosphatidylinositol glycan specific phospholipase D/3.11
O02659; Mannose binding protein C/5.76
P0CH28*; Polyubiquitin C/4.09
A8YXX7; Trefoil factor 3/4.93
Q2TBS3; Uncharacterized protein C20orf79 homolog/4.76
Q96629; Adenain/2.23
P19034; Apolipoprotein C II/4.21
Q1JP73; UPF0553 protein C9orf64 homolog/12.57
  Q9TTK6-2; Isoform 2 of Membrane primary amine oxidase/2.30
Q1JP73; UPF0553 protein C9orf64 homolog/1.95
Q56K14; 60S acidic ribosomal protein P1/Infinity
Q3SZV7; Hemopexin/2.10
Q1JQ97; Bardet Biedl syndrome 4 protein homolog/1.48
Q56K14;60S acidic ribosomal protein P1/Infinity
Q96629; Adenain/1.74
Q2KIT0; Protein HP 20 homolog/1.93
Q5E9F5; Transgelin 2/Infinity
P62803; Histone H4/11.67
Choline O46406; Primary amine oxidase lung isozyme/1.74
Q28901; 6-p-2-k-f-2-6-b-f/Infinity
Q2M2T2; Uncharacterized protein C19orf71/1.78
A2I7N3; Serpin A3 7/1.56
Q17QL1; Glucosamine 6 phosphate isomerase 2/1.48
  A5PJC4; Ubiquitin ISG15 c. e. E2 L6/1.45
Q80E01; Glutaredoxin 1/1.40
Q0VCI2; Syntaxin 19/3.81
Q0V898; Negative elongation factor E/2.4
Q05204; Lysosome associated membrane glycoprotein 1/4.03
Q56K14; 60S acidic ribosomal protein P1/8968.4
P34955; Alpha 1 antiproteinase/1.47
A2I7N2; Serpin A3 6/1.72
Q3SZJ0; Argininosuccinate lyase/1.41
Q17QL1; Glucosamine 6 phosphate isomerase 2/8.44
Control   P80012; von Willebrand factor Fragment/2.08 A2I7N0; Serpin A3 4/1.60 P21752; Thymosin beta 10/1.45
Q3SZK0; Solute carrier family 25 member 34/1.72 Q2TBS3; Uncharacterized protein C20orf79/2.01 Q3T132; Ragulator complex protein LAMTOR2/2.04
Q05204; Lysosome associated membrane glycoprotein 1/2.34   P01044-2*; Isoform LMW of Kininogen 1/2.87
  Q9TTK6-2; Isoform 2 of Membrane primary amine oxidase/2.82  
Q80E01; Glutaredoxin 1/3.37   Q58CQ9; Pantetheinase/1.58
Q05204; Lysosome associated membrane glycoprotein 1/10.89 Q3MHN5; Vitamin D binding protein/1.48  
   Q96629; Adenain/1.69
Q2KIU3; Protein HP 25 homolog 2/1.70 P56652; Inter alpha trypsin inhibitor heavy chain H3/1.58  
P02081; Hemoglobin fetal subunit beta/1.72 Q29443; Serotransferrin/1.57 P01044-2*; Isoform LMW of Kininogen 1/1.62
Q32PJ2; Apolipoprotein A IV/1.45 Q58CQ9; Pantetheinase/1.84
A2I7N2; Serpin A3 6/4.57 P21752; Thymosin beta 10/1.46
Q2KJF1; Alpha 1B glycoprotein/1.46 Q9MYP6;17 beta hydroxysteroid dehydrogenase 14/2.24
P01966; Hemoglobin subunit alpha/1.63
P02070; Hemoglobin subunit beta/1.98
A7YY73; Transcription factor MafF/5.00
E1BF81; Corticosteroid binding globulin/5.27
Control Choline LPS LPS_Choline
  1. This table shows the identified proteins with highest mean condition (left) and lowest mean condition (bottom) among experimental groups at different time points at statistically significant level (P < 0.05). Relative abundance levels of the proteins with highest mean condition, compared to the proteins with lowest mean condition, are indicated after the slash (/). Time points are indicated with underline, italic and italic + underline, for 1 h, 4 h and 48 h time points, respectively. Asterisk (*) indicates the proteins, of which, isoforms are detectable (see Additional file for the accession numbers of the isoforms). Abbreviations; c. e.: conjugating enzyme, 6-p-2-k-f-2-6-b-f; 6 phosphofructo 2 kinase fructose 2 6 bisphosphatase 3 Fragment, m-1-h; member 1 homolog, U-p-C19orf71-h; Uncharacterized protein C19orf71 homolog, P-g-s-p-d; Phosphatidylinositol glycan specific phospholipase D